Eli Lilly Starts Clinical Testing Of Coronavirus COVID-19 Therapies Baricitinib, LY3127804
Baricitinib Research Commences in NIH-led Adaptive Coronavirus COVID-19 Treatment Trial. Eli Lilly Starts Phase 2 Trial with Anti-Ang2 in Coronavirus COVID-19 Indianapolis – On April 10th, 2020, Eli Lilly and Company (NYSE: LLY) announced it entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of … Read more